1Incentives for orphan drugs R&D in Europe and America and the enilghtenment for ChinaWANG Hong, WU Zhi-ang1681-1685,16932Investigation and analysis of healthcare patents distribution and trendZHU Xiu-huang, YI Xiang-hua, XUE Fang-fang, LI Qiong1686-16933Analysis of patent layout by Sanofi Aventis pharmaceutical company in ChinaYANG Shu-jie, HUA Si-hua, YUAN Hong-mei, LIAN Gui-yu1694-16974Analysis of patent application of the new HCV inhibitor sofosbuvir in ChinaMAO Dan1698-17015Research progress of in vitro systems for neurotoxicity evaluation1702-17066Determination of insulin precursor in recombinant human insulin by RP-HPLCDING Xiao-li, GE Yu-peng, ZHANG Hui, LIANG Cheng-gang1707-17107Preparation and antibacterial activity of antimicrobial peptide CA gelLIU Chao-yong, XIAO Yun-zhi, LI Xiao-rong, WAN Lu, LI Rui-sheng, HAN Jin, YUAN Hai-long1711-1714,17198A method for determination of biological activity of PCSK9 monoclonal antibody1715-17199Anti-IgD antibody and its role in autoimmune diseasesCHEN Heng-shi, WU Yu-jing, HUANG Qiong, CHEN Wen-sheng, WEI Wei1720-1723,174110Discussion on investigation of foreign matter introduced by parenteral manufacturing processLI Da-wei, HUANG Shao-feng, ZHENG Qiang, SUN Jing-lin1724-1726,175311Current situation and the trend in impurity profiling of chemical drugsHU Chang-qin1727-173412Advance in study of long-acting glucagon-like peptide-1 receptor agonistsLIN Xuan, WANG Jun-ling, LI Tai-ming, WU Yan-zhuo, XU Ming-bo1735-174113MRI-based dual molecular imaging techniques and theranosticsJIANG Dan-dan, ZHANG Na1742-1746,177614Interpretation of "Good Clinical Practice (revised draft) "1747-1749,178515Comparison and analysis of issues existing in informed consent forms of clinical trials sponsored by foreign and domestic enterprisesBAI Cai-zhen, FAN Xiao, REN Pei-juan, LI Na1750-175316Research on protection of paticipants' rights and interests in clinical trials: a case study of a clinical trial agency of one 3A grade hospitals in BeijingZHENG Jun, LI Yi-ting1754-175917Clinical efficacy of crizotinib for brain metastases in patients with advanced ALK-rearranged non-small cell lung cancerLIU Yu-tao, WANG Zi-ping, HU Xing-sheng, LI Jun-ling, HAO Xue-zhi, SHI Yuan-kai1760-1764,177018Synthesis and biological evaluation of novel phenylacetamides analogs as histone acetylation enzyme inhibitorsJIA Zhong, ZHANG Yang, LI Jing, ZHAO Jing-si, XI Na, MA Shang-xian, HE Dian1765-177019In vitro evaluation of RGD peptide-modified polyglutamic acid-cisplatin conjugateXIONG Ye-rong, TU Jia-sheng, LIU Kai-shuang, ZHANG Meng-ze1771-177620Preparation and in vitro evaluation of raloxifene hydrochloride self-microemulsionLU Xiu-xia, LI Wei-zhen, HE Lin, LUO Hai-shan, PAN Yu-fang1777-1785 